Efficacy of Cabozantinib in Patients With Advanced Renal Cell Carcinoma With Bone Metastasis Assessed by Modified MD Anderson Criteria: An Open-Label Phase 2 Study - PubMed
4 hours ago
- #Renal Cell Carcinoma
- #Cabozantinib
- #Bone Metastasis
- Cabozantinib treatment was assessed for efficacy in advanced renal cell carcinoma (aRCC) patients with bone metastasis in a phase 2 study.
- The objective response rate (ORR) for bone target lesions was 6.5%, with a disease control rate (DCR) of 90.3%.
- Median progression-free survival (PFS) was 11.9 months, and overall survival (OS) was 24.9 months.
- Common adverse events included palmar-plantar erythrodysesthesia syndrome (54.8%), malaise (45.2%), and hypertension (32.3%).
- No new safety issues were identified, and health-related quality of life remained generally stable during treatment.